Trial Profile
PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH AN ALLOGENEIC B7.1/HLA-A1 TRANSFECTED TUMOR CELL VACCINE (PT 107) IN PATIENTS WITH STAGES IIIB/IV NON-SMALL CELL LUNG CANCER THAT HAVE COMPLETED FIRST LINE CHEMOTHERAPY.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs PT 107 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Nov 2017 According to a Pique Therapeutics media release, data will be presented at at the Society for the Immunotherapy of Cancer's (SITC) 32nd Annual Meeting.
- 07 Nov 2017 Results presented in a Pique Therapeutics Media Release.
- 27 Oct 2011 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India.